I-SPY 2: optimising cancer drug development in the 21st century

Autor Bartsch, Rupert, de Azambuja, Evandro
Vydáno v ESMO Open (2016)

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?

Autor Franzoi, Maria Alice, de Azambuja, Evandro
Vydáno v ESMO Open (2020)

Threat posed by unproven drugs in medical oncology

Autor Pondé, Noam, Ades, Felipe, de Azambuja, Evandro
Vydáno v ESMO Open (2016)

Phosphoethanolamine and the danger of unproven drugs

Autor Pondé, Noam, de Azambuja, Evandro, Ades, Felipe
Vydáno v Ecancermedicalscience (2016)

Male breast cancer: finding the way in this uncommon path

Autor Maurer, Christian, Martel, Samuel, de Azambuja, Evandro
Vydáno v ESMO Open (2017)

Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?

Autor Poggio, Francesca, Lambertini, Matteo, de Azambuja, Evandro
Vydáno v ESMO Open (2018)

Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?

Autor Lambertini, Matteo, Viglietti, Giulia, de Azambuja, Evandro
Vydáno v ESMO Open (2018)

How I treat metastatic triple-negative breast cancer

Autor Caparica, Rafael, Lambertini, Matteo, de Azambuja, Evandro
Vydáno v ESMO Open (2019)

Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer

Autor Eiger, Daniel, Brandão, Mariana, de Azambuja, Evandro
Vydáno v ESMO Open (2020)

CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?

Autor Agostinetto, Elisa, Caparica, Rafael, de Azambuja, Evandro
Vydáno v ESMO Open (2020)

Twenty years of anti-HER2 therapy-associated cardiotoxicity

Autor Pondé, Noam F, Lambertini, Matteo, de Azambuja, Evandro
Vydáno v ESMO Open (2016)

How Long is Enough – Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer

Autor Pinto, Ana Catarina, de Azambuja, Evandro, Piccart-Gebhart, Martine
Vydáno 2013

Oncofertility counselling in premenopausal women with HER2-positive breast cancer

Autor Lambertini, Matteo, Demeestere, Isabelle, Viglietti, Giulia, de Azambuja, Evandro
Vydáno v Oncotarget (2019)

The Exciting New Field of HER2-Low Breast Cancer Treatment

Autor Eiger, Daniel, Agostinetto, Elisa, Saúde-Conde, Rita, de Azambuja, Evandro
Vydáno v Cancers (Basel) (2021)

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

Autor Snoj, Natasa, Bedard, Philippe L, de Azambuja, Evandro, Cardoso, Fatima, Piccart, Martine
Vydáno 2009

Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA

Autor Ades, Felipe, Senterre, Christelle, Zardavas, Dimitrios, de Azambuja, Evandro, Popescu, Razvan, Piccart, Martine
Vydáno v PLoS One (2017)

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib

Autor Kourie, Hampig Raphael, El Rassy, Elie, Clatot, Florian, de Azambuja, Evandro, Lambertini, Matteo
Vydáno v Onco Targets Ther (2017)

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives

Autor Caparica, Rafael, Lambertini, Matteo, Pondé, Noam, Fumagalli, Debora, de Azambuja, Evandro, Piccart, Martine
Vydáno v Ther Adv Med Oncol (2019)

Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer

Autor Curigliano, Giuseppe, de Azambuja, Evandro, Lenihan, Daniel, Calabrò, Maria Grazia, Cardinale, Daniela, Cipolla, Carlo Maria
Vydáno v Oncologist (2019)

Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience

Autor Franzoi, Maria Alice, Saúde-Conde, Rita, Ferreira, Sofia Cristóvão, Eiger, Daniel, Awada, Ahmad, de Azambuja, Evandro
Vydáno v Breast (2021)